Drugs / TBI-223
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06192160 | Mar 2025 → Nov 2026 expected | pulmonary tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT04865536 Comparator | Feb → May 2021 | pulmonary tuberculosis | Global Alliance for TB Drug Development | Completed | No outcome recorded |
| Phase 1 | NCT03758612 Comparator | Jan 2019 → Mar 2020 | pulmonary tuberculosis | Global Alliance for TB Drug Development | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TBI-223 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04865536 ↗ |
| Modality | Small molecule | “TBI-223 is an oxazolidinone antibiotic under clinical development for the treatment of tuberculosis.” PMID 40067046 ↗ Mar 2025 |
| Route | Oral | “TBI-223 oral suspension, orally administered.” NCT03758612 ↗ |